

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司
SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON FRIDAY, 20 MAY 2022

The board of directors (the “**Board**”) of Sinopharm Group Co. Ltd. (the “**Company**”) is pleased to announce that the extraordinary general meeting (the “**EGM**”) was held physically at 9:00 a.m. on Friday, 20 May 2022 at Room 601, Bldg 1, Yard 19, Taiyanggong Middle Road, Chaoyang District, Beijing, the People’s Republic of China (the “**PRC**”) and by live online webcast for shareholders.

The poll results in respect of the resolutions proposed at the EGM are as follows:

ORDINARY RESOLUTIONS		Number of Valid Votes (%)	
		FOR	AGAINST
1.	THAT the actual transaction amount between the Group and China National Pharmaceutical Group Co., Ltd. (“CNPGC”) and its subsidiaries and associates (excluding the Group)(the “CNPGC Group”) under the procurement framework agreement entered into between the Company and CNPGC on 22 October 2020 (the “ 2020 Procurement Framework Agreement ”) for the year ended 31 December 2021 as well as the actual transaction amount between the Group and CNPGC Group under the sales framework agreement entered into between the Company and CNPGC on 22 October 2020 (the “ 2020 Sales Framework Agreement ”) for the year ended 31 December 2021 (collectively, the “ 2021 Actual Transaction Amounts ”) , be and are hereby approved, confirmed and ratified.	917,423,661 (98.939852%)	9,830,263 (1.060148%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
2.	THAT the proposed new annual caps for the transactions contemplated under the 2020 Procurement Framework Agreement for the two years ending 31 December 2023, be and are hereby approved and confirmed.	914,935,241 (98.671700%)	12,316,683 (1.328300%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
3.	THAT the proposed new annual caps for the transactions contemplated under the 2020 Sales Framework Agreement for the two years ending 31 December 2023, be and are hereby approved and confirmed.	914,935,641 (98.671701%)	12,316,683 (1.328299%)
As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

As at the date of the EGM, the total number of issued shares of the Company was 3,120,656,191 shares.

In accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”), China National Pharmaceutical Group Co., Ltd. and its associates holding an aggregate of 1,778,845,451 shares, representing approximately 57.00% of the

total issued shares of the Company, are required to abstain, and have abstained, from voting on the above resolutions proposed at the EGM due to their material interests in these resolutions. Accordingly, the total number of shares entitling the holders to attend and vote for or against the above resolutions at the EGM was 1,341,810,740 shares.

There were no shares entitling the holders to attend and abstain from voting in favour of any resolution proposed at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules. No parties had stated their intention in the circular dated 5 May 2022 of the Company to vote against or to abstain from voting on the resolutions proposed at the EGM.

Shareholders and authorized proxies holding an aggregate of 927,253,924 shares, representing 69.10% of the total shares entitled to vote at the EGM, were present at the EGM. The holding of the EGM was in compliance with the requirements of the Company Law of the PRC and the articles of association of the Company. The EGM was chaired by Mr. Yu Qingming, the Chairman of the Board. Except for Mr. Liu Yong, Mr. Hu Jianwei and Mr. Deng Jindong who did not attend the EGM due to other business arrangements, all other directors have attended the EGM.

In compliance with the requirements of the Hong Kong Listing Rules, Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as scrutineer for the vote-taking at the EGM.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
20 May 2022

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.